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Immunophenotypic Analysis Reveals
Differences in Circulating Immune Cells in the
Peripheral Blood of Patients with Segmental and
Nonsegmental Vitiligo
Marcella Willemsen1, Nicoline F. Post1, Nathalie O.P. van Uden1, Vidhya S. Narayan1, Saskia Chielie1,
E. Helen Kemp2, Marcel W. Bekkenk1 and Rosalie M. Luiten1
Accumulating studies have indicated immune-based destruction of melanocytes in both segmental vitiligo (SV)
and non-SV (NSV). Whereas SV often occurs unilaterally during childhood and stabilizes after an initial period
of activity, the disease course of NSV is usually slowly progressive, with new lesions occurring bilaterally during
life. This suggests an involvement of distinct pathophysiology pathways, specifically increased systemic im-
mune activation in patients with NSV but not in patients with SV. This research aimed to identify the differences
in immune cells in the blood of patients with SV and NSV through immunophenotyping of circulating cells.
Regulatory T cells were unaffected in patients with SV compared with that in healthy controls but decreased in
patients with NSV. In patients with NSV, the reduction in regulatory T cells was associated with the presence of
other systemic autoimmune comorbidities, which were less present in SV. Similarly, the absence of a
melanocyte-specific antibody response in patients with SV suggests less involvement of B-cell immunity in SV.
These data show that in contrast to patients with NSV, no increased systemic immunity is found in patients with
SV, indicating that SV pathogenesis is associated with a localized cytotoxic reaction targeting epidermal
melanocytes.
Journal of Investigative Dermatology (2021) -, -e-; doi:10.1016/j.jid.2021.05.022
INTRODUCTION
Vitiligo is the most common skin depigmenting disorder
characterized by white patches resulting from the loss of
pigment-producing cells, melanocytes (Bergqvist and
Ezzedine, 2020). It affects approximately 0.5% of the gen-
eral population with no apparent differences in rates of
occurrence according to sex, skin type, or ethnicity (Boniface
et al., 2018). An international consensus classified vitiligo
into two subtypes (Ezzedine et al., 2012). The commonest
form, nonsegmental vitiligo (NSV), shows symmetrical
depigmentation of the body. Contrary, segmental vitiligo (SV)
is less common (10%) and is characterized by a unilateral
distribution. In addition, NSV shows an unpredictable dis-
ease course, whereas SV typically stabilizes a few months
after onset. Altogether, this suggests that distinct
pathophysiology pathways might be involved, which could
clarify the differences in clinical presentation and disease
course.
Initially, somatic mosaicism, neurogenic mechanisms, and
oxidative stress were suspected to be the underlying cause of
SV (Speeckaert et al., 2020). Only recently, immune-
mediated pathophysiology of SV has been recognized.
Increasing evidence has shown immune-based cytotoxic
destruction of melanocytes in SV, with lesional IFN-
geproducing melanocyte antigen‒reactive CD8þ T-cell in-
filtrates migrating to the basal layer (Attili and Attili, 2013;
Shin et al., 2016; van Geel et al., 2010). Although NSV is
closely associated with other autoimmune disorders, for
example, thyroid disease and alopecia areata, systemic
autoimmune comorbidities are less common in patients with
SV (Dahir and Thomsen, 2018; Speeckaert et al., 2020).
Nevertheless, localized skin inflammation, for example,
linear morphea, is repeatedly observed in patients with SV,
implying a local inflammatory response (Speeckaert et al.,
2020). The comparison between SV and NSV provides a
unique setting to study whether antimelanocyte immunity
remains localized in SV and spreads systemically in NSV.
A study on gene expression profiles of patients with SV and
NSV and of healthy individuals showed that differentially
expressed genes in SV were involved in the adaptive immune
response, whereas in NSV, the regulation of the innate im-
mune response and B-cell differentiation and activation was
more prominent, implying that SV and NSV may utilize
different immune responses and mechanisms for melanocyte
destruction (Wang et al., 2016). Concomitantly, the blood of
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patients with NSV showed a decrease in regulatory T cells
(Tregs) and an increase in unswitched memory B cells
compared with healthy control blood, which was related to
disease activity (Raam et al., 2018). Considering the positive
correlation between switched memory B cells and circulating
T follicular helper (cTfh) cells, patients with active NSV show
activation of germinal centers and faster B-cell isotype
switching (Raam et al., 2018). Despite data showing
involvement of B cells and germinal center reactions, the
correlation to a humoral response remained unstudied.
To our knowledge, analysis of circulating immune cells,
involvement of a humoral response, and germinal center
reactions in SV have not been fully characterized. Whereas
associated autoimmune diseases are more common in NSV
(Alkhateeb et al., 2003; Gill et al., 2016; Hadi et al., 2020;
Spritz and Andersen, 2017), evidence points to a temporary
cytotoxic response targeting melanocytes in SV, suggesting
differences in systemic immune cell dysregulation between
patients with SV and those with NSV.
This study aimed to compare the differences in cellular and
humoral adaptive immunity and innate immunity in human
blood of patients with SV and NSV that can contribute to
clinical presentation and disease progression. Our results
show no increased systemic immunity in patients with SV, in
contrast to that in patients with NSV, and points to localized
immune-based cytotoxic destruction of melanocytes.
RESULTS
Demographics and clinical characterization of study
subjects
The characteristics of the participants are shown in Table 1.
Patients with SV had an average age of 34 years, which is
higher than the average age of the general SV population
because of the age 18 years inclusion criterion. SV had
stabilized in our patient cohort, for at least 12 months. To
focus our comparative study on the differences between SV
and NSV without the interference of active versus stable
vitiligo disease activity, we compared stable patients with SV
with stable patients with NSV. The majority of included pa-
tients with SV had type-2 skin, and only one patient had al-
opecia areata as autoimmune comorbidity. Patients with NSV
had stable disease and an average age of 43 years; the ma-
jority of patients had a type-2 or -3 skin type, and 6 of the 22
patients (27.2%) showed autoimmune comorbidities. Patients
Table 1. Patient Characteristics
Healthy Donor SV NSV
P-Value1n % IQR/SD n % IQR/SD n % IQR/SD
Total 22 12 22
Age
<25 2 9.1 3 25 1 4.5
25e50 17 77.3 8 66.7 14 63.6
>50 3 13.6 1 8.3 7 31.8
Mean 36 (23e48) 34 (22e46) 43 (29e57) >0.05
Sex >0.05
Male 6 27.3 9 75 11 50
Female 16 72.7 3 25 11 50
Skin type2 >0.05
Type 1 0 0 1 4.5
Type 2 13 59.1 8 66.7 12 54.5
Type 3 7 31.9 3 25 8 36.4
Type 4 1 4.5 1 8.3 0
Type 5 1 4.5 0 1 4.5
Type 6 0 0 0
Comorbidities
Thyroid disease 0 3 13.63
Alopecia Areata 1 8.3 0




Other4 0 1 4.53
Vitiligo age of onset (y) mean 25 14.8 33 15.6 >0.05
Disease duration (y) median 4 (2.3e12.3) 8 (4e12.5) >0.05
% Affected body surface area median 0.75 (0.5e1.9) 1 (0.9e3.9) >0.05
Abbreviations: CREST, calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia; DM, diabetes mellitus; IBD,
inflammatory bowel disease; IQR, interquartile range; NSV, nonsegmental vitiligo; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; SLE, systemic
lupus erythematosus; SV, segmental vitiligo.
1P-value tested with Student’s t-test or Mann‒Whitney test.
2Skin type according to the Fitzpatrick skin scale.
3One patient with NSV showed multiple autoimmune comorbidities (hypothyroidism, DM type 1, and colitis ulcerosa).
4Other specified, including Addison’s disease, arthritis psoriatica, autoimmune hepatitis, IBD, celiac, CREST, morphea, pernicious anemia, PMR,
sarcoidosis, scleroderma, Sjogren’s Syndrome.
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with SV and NSV did not differ in age of onset, disease
duration, and affected body surface area. Healthy controls
were comparable with regard to age, sex, and skin type with
the patients with vitiligo.
Patients with NSV with secondary autoimmune
comorbidities have less circulating Tregs
Perturbations in Treg numbers and function in vitiligo remain
indistinct. Some studies report systemically reduced Tregs in
NSV (Ben Ahmed et al., 2012; Dwivedi et al., 2013; Giri
et al., 2020; Hegab and Attia, 2015; Lili et al., 2012; Raam
et al., 2018), whereas others show that abundance of Tregs
in NSV trends toward an increase (Abdallah and Saad, 2009;
Moftah et al., 2014). Moreover, Treg involvement in SV re-
mains unstudied. Therefore, we studied systemic Treg and
type-1 Treg numbers and IL-10 production in our cohort of
patients with SV and NSV and in healthy donor samples. The
gating strategy for Tregs is depicted in Supplementary
Figure S1. Circulating Tregs were significantly decreased in
the blood of patients with NSV compared with the blood of
those with SV and those of healthy controls (Figure 1a).
However, IL-10 production by Tregs, measured as IL-10þ
cells after intracellular FACS staining, was not affected in
these patients (Figure 1a). The level of Tregs in patients with
SV did not differ from that in healthy controls (Figure 1a). We
verified these findings on the RNA expression level and in an
independent patient cohort using the RNA-sequencing data-
set from Wang et al. (2016). This dataset contains 20 patients
with SV, 20 patients with NSV, and 20 healthy control in-
dividuals (within each patient group, 5 patients were pooled
into a new sample, giving a total of 4 samples) (Wang et al.,
2016). Gene expression profiles of patients with NSV and SV
and of healthy individuals were then analyzed for the pres-
ence of a Treg gene expression signature. For this, we made
use of a gene signature used to discriminate between Tregs
(CD25high) and conventional CD4þ T cells (CD25e)
(Niedzielska et al., 2018). This gene signature comprises 25
genes, of which 21 genes are upregulated and 4 genes are
downregulated on Tregs compared with those on conven-
tional CD4þ T cells (Supplementary Table S1). Similar to
cellular Treg analysis, patients with NSV showed decreased
expression of the Treg signature compared with healthy in-
dividuals (P < 0.05) (Figure 1b). Because of the large spread
among SV samples, comparing Treg levels in patients with
NSV and in those with SV did not reach significance (P ¼
0.08) (Figure 1b).
Because systemic autoimmune comorbidities might influ-
ence circulating Treg numbers, we compared Treg levels in
patients with NSV with or without comorbidities as indicated
in Table 1. Patients with NSV with autoimmune comorbidities
showed significantly fewer Tregs than patients with NSV
without autoimmune comorbidities (Figure 1c), suggesting
that impaired Treg numbers might be the consequence of
secondary autoimmune responses and not specific to vitiligo
pathogenesis. Treg levels in patients with NSV without
autoimmune comorbidities still trended toward a decrease
compared with those in healthy controls, but this did not
reach significance in our patient cohort size (P ¼ 0.09; data
not shown). Nevertheless, gene expression patterns of pa-
tients with NSV showed a less pronounced Treg signature,
even when autoimmune conditions were absent (the patient
cohort of Wang et al. [2016] only includes patients with no
history of any other autoimmune condition) (Figure 1b).
In contrast to Tregs, the percentage of type-1 Tregs did not
demonstrate significant differences between the studied
groups; nonetheless, IL-10‒producing type-1 Tregs were
increased in patients with SV (Figure 1d). To conclude, these
results further support that Tregs but not type-1 Tregs are
negatively affected in (some) patients with NSV, which may
facilitate the development of autoimmune comorbidities. In
contrast, Tregs remain unaffected in patients with SV,
consistent with less systemic autoimmune comorbidities in
patients with SV.
Antibody responses against melanocyte antigens are present
only in patients with NSV
Antibody responses against melanocyte antigens, for
example, tyrosinase (TYR) and TRP-2, have been found in the
sera of patients with NSV (Kemp et al., 2007). However, sera
from patients with SV have rarely been tested for the presence
of autoantibodies. To test reactivity to melanocyte antigens in
patients with SV and NSV, sera were evaluated for antibody
reactivity against TYR, TYRP1, TYRP2, PMEL, TYR hydroxy-
lase, MART-1, and MCHR1. Antibodies against selected
melanocyte antigens were present in the circulation of a
significant proportion of patients with NSV (Figure 2). In total,
8 of 22 (36%) patients with NSV were found to have anti-
melanocyte antibody responses (Supplementary Table S2).
Moreover, three of eight patients showed antibody reactivity
to several melanocyte antigens (Supplementary Table S2).
Patients with NSV with antibody responses against the anti-
gens mentioned earlier were not significantly different from
patients with NSV without autoantibodies regarding age, sex
distribution, skin type, presence of secondary autoimmune
comorbidities, vitiligo age of onset, disease duration, and
percentage of affected body surface area (Supplementary
Table S3). Contrary, none of the patients with SV showed
an antibody response (Figure 2), indicating that the presence
of a humoral immune response to melanocyte antigens is
limited to patients with NSV.
Patients with SV have fewer circulating antibody-producing
plasmablasts
We subsequently analyzed whether the absence of antibody
responses in SV is also reflected in less B-cell activation and
plasma-cell differentiation. The gating strategy for B cells is
depicted in Supplementary Figure S1. The percentage of total
B cells (CD3e CD19þ) was comparable between patients
with vitiligo and healthy individuals (Figure 3a). Similarly,
naive B cells and unswitched and switched memory B cells
did not demonstrate significant differences between the
studied groups (Figure 3a), implying that B cells seem to
mature similarly in patients with vitiligo and in healthy in-
dividuals. Similarly, transitional B cells did not differ between
patients with SV and NSV nor the patients and the healthy
controls (Figure 3b). However, plasmablasts were signifi-
cantly decreased in blood from patients with SV compared
with healthy donor blood (Figure 3c). Concomitantly, plas-
mablasts showed a trend toward a decrease in patients with
SV compared with that in patients with NSV, suggesting that
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patients with SV have fewer circulating antibody-producing
cells.
Patients with SV have more cTfh2 and cTfh17 cells but no
increase in the number of active cTfh cells
Our data so far indicate that patients with SV have no
melanocyte-specific antibody response and a diminished
humoral response, illustrated by fewer circulating plasma-
blasts (Figures 2 and 3c). To verify whether this reduced
plasmablast differentiation stems from reduced germinal
center help, we analyzed the presence of cTfh cells. Levels of
both cTfh cells and active cTfh cells (PD-1þ ICOSþ) were
unaffected in patients with NSV compared with that in
healthy control individuals. Instead, the number of cTfh cells
were significantly increased in patients with SV compared
with that in patients with NSV (Figure 4a). Similarly, the
number of cTfh cells with an active phenotype were
increased in patients with SV compared with those in
both patients with NSV and healthy controls (P < 0.05)
(Figure 4a).
On the basis of the expression of CXCR3 and CCR6, cTfh
cells can be classified into cTfh1, cTfh2, and cTfh17 cells
(Supplementary Figure S1) (Koutsakos et al., 2019). These
cells differ in their ability to provide help to naive and
memory B cells, and thus the abundance of specific cTfh cell
subsets might be as important as total cTfh cell levels. In
blood, cTfh1 cells did not show significant differences be-
tween the studied groups (Figure 4b). Contrary, cTfh2 and
cTfh17 cells, which are superior IL-21 producers to cTfh1
cells and especially provide help to naive B cells, were
significantly increased in patients with SV compared with
those in patients with NSV and in healthy controls (P < 0.05)
(Figure 4b). More importantly, patients with SV did not show
an increase in active cTfh2 and cTfh17 cells (Figure 4c).
Figure 1. Comparison of circulating Treg subpopulations in patients
with vitiligo (a) The percentage of Tregs among CD4þ T cells (left) and
IL-10‒producing cells among Tregs (right) in HD (n ¼ 22), patients with
SV (n ¼ 12), and patients with NSV (n ¼ 20). (b) Expression of the Treg
core gene signature in HD (n ¼ 20), patients with SV (n ¼ 20), and
patients with NSV (n ¼ 20) (within each group, five samples were
pooled into a new sample). The genes included in this Treg core
signature are included in Supplementary Table S1. (c) The percentage of
Tregs among CD4þ T cells in patients with NSV without (no Comorb.,
n ¼ 16) or with comorb. (n ¼ 6). (d) The percentage of Tr1 among
CD4þ T cells (left) and IL-10‒producing cells among Tr1 (right) in HD,
patients with SV, and patients with NSV. Results are shown as individual
dot plots with a line as median and 95% CI for a, c, and d or median
and minimum and maximum for b. ANOVA and Student’s t-test are
significant as indicated; *P < 0.05. CI, confidence interval; Comorb,
autoimmune comorbidity; HD, healthy control; NSV, nonsegmental
vitiligo; SV, segmental vitiligo; Tr1, type-1 regulatory T cell; Treg,
regulatory T cell.
Figure 2. Presence of melanocyte-specific antibody responses in patients
with vitiligo. Sera of HD (n ¼ 30), patients with SV (n ¼ 12), and patients with
NSV (n ¼ 20) were analyzed in radio-binding assays for the presence of
antibodies against TYR, TRP1, TRP2, PMEL, TH, MART-1, and MCHR1. The
antibody index for each individual patient is shown and is calculated as
c.p.m. immunoprecipitated by tested serum divided by the mean c.p.m.
immunoprecipitated by the group of HD sera. Each serum was tested in at
least three independent experiments. Next, the mean antibody index was
calculated from these values. Patient sera with an antibody index above the
upper limit of normal (mean antibody index þ 3  SD of the HD individuals)
were regarded as positive for antibody reactivity. c.p.m., count per minute;
HD, health control; NSV, nonsegmental vitiligo; SV, segmental vitiligo; TH,
tyrosinase hydroxylase; TYR, tyrosinase.
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Concomitantly, active cTfh cell subsets did not differ between
patients with NSV and healthy individuals (Figure 4c).
Because the provision of B-cell help is limited to activated
cTfh cells and the percentage of active cTfh1, cTfh2, and
cTfh17 cells do not differ between SV and NSV, it seems that
both vitiligo cohorts show normal germinal center help that is
not different from that of the healthy controls.
As for Treg numbers, systemic autoimmune comorbidities
might affect cTfh cell levels and activation status. NSV is
closely associated with other autoimmune conditions,
whereas these are less common in patients with SV (Dahir
and Thomsen, 2018; Speeckaert et al., 2020). These
comorbidities may involve humoral responses and increased
B-cell help from cTfh cells. Indeed, when patients with NSV
were divided into subgroups according to the presence of
secondary autoimmune comorbidities, it was evident that
systemic autoimmune comorbidities were associated with
increased percentages of active cTfh2 cells (P < 0.05) and
cTfh17 cells (P ¼ 0.07) but not with cTfh1 cells (Figure 4d).
Collectively, our results show increased cTfh2 and cTfh17
cell numbers in SV but no increased germinal center re-
actions in human vitiligo. Consistent with an increase in
activated cTfh2 and cTfh17 cell subsets in type-I diabetes and
Figure 3. Distribution of peripheral B-cell subsets in patients with vitiligo.
(a‒c) The percentage of B cells among lymphocytes, naive B cells, unswitched
memory B cells, and switched memory B cells among (a) B cells, (b)
transitional B cells, and (c) plasmablasts among B cells in HD (n ¼ 22),
patients with SV (n ¼ 12), and patients with NSV (n ¼ 20). Results are shown
as individual dot plots with means  SEM. ANOVA test is significant as
indicated; *P < 0.05. HD, health control; NSV, nonsegmental vitiligo; SV,
segmental vitiligo.
Figure 4. Comparison of cTfh cell subsets in patients with vitiligo. (a‒c) The
percentage of cTfh cells among (a) CD4þ cells and active (PD-1þ ICOSþ) cTfh
cells, (b) cTfh cell subsets and active cells within CD4þ cells, and (c) cTfh cell
subsets in HD (n ¼ 22), patients with SV (n ¼ 12), and patients with NSV (n ¼
20). (d) The percentage of active cells among cTfh cell subsets in patients with
NSV without (no comorb., n ¼ 16) or with Comorb. (n ¼ 6). Results are
shown as individual dot plots with means  SEM. ANOVA and Student’s t-test
are significant as indicated; *P < 0.05. Comorb., autoimmune comorbidity;
cTfh, circulating T follicular helper; HD, health control; NSV, nonsegmental
vitiligo; SV, segmental vitiligo.
M Willemsen et al.
Immunophenotypic Analysis of Vitiligo Blood
www.jidonline.org 5
thyroid disease (Gensous et al., 2018), enhanced cTfh cell
activation in patients with NSV with secondary autoimmune
comorbidities seems to result from those rather than from skin
autoimmunity.
Patients with vitiligo do not differ from healthy controls with
regard to circulating NK cells
Besides aberrations in the adaptive immune response, innate
immunity is suggested to be involved in NSV pathogenesis as
well but left unstudied in patients with SV. The gating strategy
for NK cells is depicted in Supplementary Figure S1. Systemic
NK cell levels were not different in both vitiligo subtypes
compared with that in healthy control blood (Figure 5a).
Expression of the activating NK cell receptor, NKG2D, on NK
cells and cytotoxic CD56dim NK cells was significantly
decreased in patients with NSV compared with that in healthy
controls but unaffected on cytokine-producing CD56bright NK
cells (Figure 5b). However, in the blood of patients with SV, no
difference in NKG2D expressionwas seen comparedwith that
in the blood of healthy controls. Because NKG2D can be
expressed by CD8þ T effector memory cells and because an
increased expression has been observed in active NSV skin
(Jacquemin et al., 2020), we analyzed NKG2D expression by
peripheral CD3þ T cells. No significant differences in the
proportion of NKG2DþCD3þ T cells were seen in the blood of
patients with NSV compared with that in the blood of patients
with SV and healthy controls (data not shown). Because NK
cells were unaffected in patients with SV, innate immunity
seems to be less involved in SV pathogenesis.
DISCUSSION
This study provides important insights into the differences
between SV and NSV pathogenesis and shows that in contrast
to NSV, SV does not involve systemic immune activation. We
found that Tregs are less abundant in patients with NSV than
in healthy controls but did not differ in patients with SV.
Furthermore, a humoral response and germinal center re-
actions were not observed in patients with SV. This is
consistent with fewer autoimmune comorbidities in patients
with SV and points to a local autoimmune reaction.
Previous studies have shown the presence of melanocyte-
specific antibodies in some patients with NSV (Kemp et al.,
2007), whereas this remained largely unstudied in patients
with SV. This work shows that the involvement of a humoral
response against melanocyte antigens is restricted to patients
with NSV. The absence of a melanocyte-specific antibody
response is consistent with the observation that there is no
systemic immune activation in patients with SV. Although
autoantibodies were found in some patients with NSV, we
hypothesize that this is an underestimation because we tested
only seven common melanocyte autoantibody targets.
Indeed, in immunoprecipitation experiments with melano-
cyte extracts, 100% of patients with NSV and 0% of healthy
controls were found to have antimelanocyte antibodies in
their sera (Naughton et al., 1983). In addition, incidence and
level of autoantibodies have been correlated with disease
activity and the extent of the disease, meaning that patients
with active vitiligo and patients with 5e10% skin depig-
mentation are more likely to have circulating antimelanocyte
antibodies (Harning et al., 1991; Naughton et al., 1986).
Tregs induce anergy in melanocyte-specific T cells in
healthy individuals (Maeda et al., 2014). More importantly, it
is assumed that melanocyte-reactive CD8þ T cells escape
anergy by loss of coinhibitory CTLA-4 expression in NSV.
Similarly, we show that Treg numbers are decreased in pa-
tients with stable NSV, most prominently in patients with
secondary autoimmune comorbidities, as hypothesized
earlier (Le Poole and Mehrotra, 2017). Even in the absence of
autoimmune comorbidities, we found that patients with NSV
still show a trend toward a decrease in Treg numbers and
signatures. In a previous study, the abundance and activity of
circulating Tregs in patients with NSV were shown to be
similar to those in healthy controls but reduced in the skin of
patients with NSV, explained by the failure of Tregs to home
to the skin in vitiligo (Klarquist et al., 2010). Contrary to our
cohort, half of these patients showed progressive disease and
were under treatment at the moment of collecting blood
samples. Therefore, these results might be explained by
different disease activity. This highlights the importance of
reporting these patient characteristics in great detail. Because
numerous studies have not clearly reported the presence or
absence of secondary autoimmune comorbidities or disease
activity while studying Tregs in NSV, it is difficult to place
results into context because the greatest differences are seen
in those with other autoimmunities.
The involvement of NK cells in vitiligo has been suggested
by previous studies. RNA analysis of NSV skin biopsies
revealed high expression of genes of the innate immune
system, especially NK cells, compared with that in healthy
skin, and more NK cells were found in both lesional and
nonlesional NSV skin (Yu et al., 2012). Similarly, NK cells
were shown to be significantly increased in the blood of
patients with stable NSV compared with that in healthy
Figure 5. Distribution of circulating NK cells in patients with vitiligo. (a) The
percentage of NK cells among CD45þ cells, CD56bright cells, and CD56dim
cells among NK cells and (b) the percentage of NKG2Dþ cells among NK
cells, CD56bright cells, and CD56dim cells in HD (n ¼ 22), patients with SV
(n ¼ 12), patients with NSV (n ¼ 20). (b). Results are shown as individual dot
plots with means  SEM. ANOVA tests are significant as indicated; *P < 0.05.
HD, health control; NSV, nonsegmental vitiligo; SV, segmental vitiligo.
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controls (Tulic et al., 2019). However, we together with
others (Raam et al., 2018) did not detect increased peripheral
NK cell levels. Nevertheless, NKG2D expression by NK cells
was shown to be significantly decreased in patients with NSV,
especially on CD56dim cells, and KLRC4-KLRK1, which en-
codes NKG2D, was found to be downregulated in the blood
of patients with SV (Wang et al., 2016). In lesional NSV skin,
the stress molecules MICA/MICB (ligands for the activating
NKG2D receptor) were shown to be expressed in dermal
areas but not in nonlesional or healthy skin (Raam et al.,
2018). In addition, IFN-geproducing innate lymphoid cells
were shown to initially induce CXCR3B-mediated melano-
cyte apoptosis (Tulic et al., 2019). Recently, increased
NKG2D expression was found on skin-resident NK cells,
NKT cells, and CD8þ effector memory T cells, especially in
patients with active disease (Jacquemin et al., 2020). Con-
trary to increased NKG2D expression by CD8þ effector
memory T cells in the skin of patients with active NSV, no
significant difference in the proportion of these cells was seen
in the blood of patients with NSV compared with that of
healthy controls (Jacquemin et al., 2020). Therefore, it is
suggested that a skin factor (possibly IL-15, IFN-a) is
responsible for the promotion of NKG2D expression
(Jacquemin et al., 2020). In addition, NKG2D upregulation in
vitiligo occurs in response to insults and stress, which pri-
marily occurs in lesional skin (Plaza-Rojas and Guevara-
Patiño, 2021). Therefore, the involvement of NK cells in
NSV and SV pathogenesis remains indistinct but suggests
skin-resident NK cells to be involved in the initial initiation of
the antimelanocyte autoimmunity during active disease
rather than long-lasting systemic NK cell involvement.
To our knowledge, immunophenotypic analysis of circu-
lating immune cells in the blood of patients with SV, compared
with those in patients with NSV and in healthy individuals has
not been previously reported in the literature. Our results
strengthened the notion that immunity plays an important role
in vitiligo pathogenesis. Most importantly, our study highlights
the immunological difference between NSV and SV. NSV is
characterized by systemic immune activation, decreased Treg
levels, and the development of autoimmune comorbidities. In
contrast, the absence of systemic immune activation in pa-
tients with SV indicates that SV pathogenesis is associatedwith
a localized cytotoxic reaction against epidermal melanocytes.
MATERIALS AND METHODS
Patient material
This study was conducted in accordance with the Declaration of
Helsinki. All subjects signed written informed consent approved by
the Medical Ethics Review Committee of the Amsterdam University
Medical Centers (NL 64983.018.18). Peripheral blood samples were
obtained from patients with SV (n ¼ 12) or with stable NSV (n ¼ 22)
aged 18 years who were visiting the outpatient clinic at the
Amsterdam University Medical Center (Amsterdam, The
Netherlands) according to current vitiligo classification and disease
activity scoring (Rodrigues et al., 2017; van Geel et al., 2019).
Exclusion criterion was disease activity in the past 12 months during
standard of care treatment. Similarly, we recruited healthy control
subjects (n ¼ 20) aged 18 years. The demographic characteristics
of patients with vitiligo and healthy controls are represented in
Table 1. PBMCs were purified from whole blood by density gradient
centrifugation (LymphoPrep, Stemcell Technologies, Vancouver,
Canada) and cryopreserved before analysis.
Antibodies and flow cytometry
Fluorochrome-conjugated antibodies are specified in Supplementary
Table S4. Cell surface staining was performed in FACS buffer (PBS
supplemented with 1% BSA and 0.05% sodium azide). Subse-
quently, cells were fixed in True-Nuclear Fix (BioLegend, San Diego,
CA) and stained intranuclear in True-Nuclear Perm Buffer (Bio-
Legend), according to the manufacturer’s instructions. FACS acqui-
sition was performed on a FACSCanto II B (BD Biosciences, Franklin
Lakes, NJ) using BD FACSDiva software (BD Biosciences), and data
were analyzed using FlowJo software (Tree Star, Ashland, OR).
Gene expression analysis
The R2 Genomics Analysis and Visualization platform (http://r2.amc.
nl) was used for the analysis of gene expression profiles of patients
with NSV and SV and of the healthy individuals (GSE80009) (Wang
et al., 2016).
Radioligand-binding assays
Antibodies in serum sampleswere detected using radioligand-binding
assays. Plasmids pcDNA3-TH, pcDNA3_TYR, pcDNA3-PMEL17,
pcDNA3-MCHR1, and pcDNA-Melan-A (MART-1) were used ac-
cording to the manufacturer’s instructions in an in vitro TnT T7-
coupled Reticulocyte Lysate System (Promega, Madison, WI) with
[35S]-methionine to produce radiolabeled full-length TYR, TRP1,
TRP2, PMEL, TYR hydroxylase, MART-1, and MCHR1, respectively.
Next, radiolabeled antigens were used in radioligand-binding assays
with patient sera (n¼ 34) and healthy control sera (n¼ 30) at a 1:100
dilution. The antibody index is calculated as the count per minute
immunoprecipitated by tested serum divided by the mean count per
minute immunoprecipitated by the group of healthy control sera
(Kemp et al., 2002). Each serum was tested in at least three indepen-
dent experiments. The mean antibody index was calculated from
these values. Patient serawith an antibody index above the upper limit
of normal (mean antibody index þ 3  SD of the healthy control in-
dividuals) were regarded as positive for antibody reactivity.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software
(GraphPad Software, San Diego, CA). Comparisons were made with
ANOVA analysis, Student’s t-test, or Mann‒Whitney test. Tukey’s
multiple comparisons corrections were applied for ANOVA analysis.
P-values < 0.05 were considered statistically significant: *P < 0.05,
**P < 0.01, ***P < 0.001, and ****P < 0.0001.
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SUPPLEMENTARY MATERIALS
Supplementary Figure S1. Gating strategy for lymphocyte subpopulations.
Tregs, cTfh cells, B cells, and NK cells were analyzed in four separate flow
cytometry panels. In each panel, lymphocytes were selected as CD45þ cells
(upper row). Tregs were considered to be CD25þ FoxP3þ cells from CD4þ
cells, and Tr1 were gated as CD49bþ Lag-3þ cells from CD4þ cells (second
row). In both Tregs and Tr1, IL-10‒producing cells were studied. cTfh cells
were gated as CXCR5þ cells from CD4þ cells (third row). On the basis of the
expression of CCR6 and CXCR3, we identified cTfh1 cells (CCR6‒ CXCR3þ),
cTfh2 cells (CCR6‒ CXCR3‒), and cTfh17 cells (CCR6þ CXCR3‒). In all cTfh
subsets, we studied the activation status by the markers PD-1 and ICOS. B
cells were identified as CD19þ CD3‒ cells from CD45þ cells (fourth row). B
cells were then classified into naive B cells (IgDþ CD27‒), usm B cells (IgDþ
CD27þ), and sm B cells (IgD‒ CD27þ). Within the switched memory B-cell
population, we analyzed the immunoglobulin subtype by staining for IgM.
From B cells, we could also identify trans B cells (CD24þ CD38þ) and
plasmablasts (CD24‒ CD38þ). Finally, NK cells were considered to be CD3‒
CD56þ cells (bottom row). Within the NK cell population, we separated
CD56bright and CD56dim NK cells. Finally, we analyzed the expression of
NKG2D on these cells. cTfh, circulating T follicular helper; FSC-A, forward
scatter area; FSC-H, forward scatter height; FSC-W; forward scatter width; sm,
switched memory; SSC-A, side scatter area; SSC-H, side scatter height; SSC-
W, side scatter width; Tr1, type1 regulatory T cell; trans, transitional; Treg,
regulatory T cell, usm, unswitched memory.
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Supplementary Table S1. Differentially Expressed Genes between CD25high Tregs and Conventional CD25‒ CD4D
T Cells


























Abbreviations: Treg, regulatory T cell.
Supplementary Table S2. Antibody Indexes for Sera from Antibody-Positive Patients with NSV
Patient TYR TRP1 TRP2 PMEL TH MART-1 MCHR1
Patient 19 1.1 1.02 0.69 1.06 3.46 0.98 0.99
Patient 21 5.89 3.91 4.09 0.92 0.92 1.10 1.09
Patient 23 3.95 2.85 2.82 1.15 1.09 0.99 0.94
Patient 24 1.02 1.10 0.88 2.94 1.06 1.00 0.91
Patient 29 7.88 5.71 5.48 0.98 1.02 0.88 1.02
Patient 30 0.83 0.85 1.09 1.01 4.29 1.07 0.94
Patient 33 1.06 1.16 0.96 5.12 0.86 0.91 0.98
Patient 40 1.04 0.91 0.93 3.74 1.14 1.05 1.11
Abbreviations: TH, tyrosinase hydroxylase; TYR, tyrosinase.
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Supplementary Table S4. Used Antibodies
Marker Clone Fluorochrome Company Catalog No.
CD45 2D1 BV510 BioLegend 368526
CD3 SK7 FITC BioLegend 344804
CD56 HCD56 BV421 BioLegend 318327
CD16 3G8 PE-Cy7 BioLegend 302015
Granzyme B QA16A02 APC/Fire 750 BioLegend 372210
CD94 DX22 PE BioLegend 305506
NKG2D 1D11 APC BioLegend 320808
NKp44 P44-8 PerCP-Cy5.5 BioLegend 325113
CD27 O323 PE-Cy7 BioLegend 302838
IgD IA6-2 PE BioLegend 348204
CD19 HIB19 APC BioLegend 302212
CD24 ML5 PerCP-Cy5.5 BioLegend 311116
CD38 HIT2 BV421 BioLegend 303526
IgM MHM-88 APC/Fire 750 BioLegend 314546
CXCR5 J252LD4 PE BioLegend 356904
CXCR3 G025H7 PerCP BioLegend 353740
CCR7 G043H7 BV421 BioLegend 353208
CCR6 G034E3 APC BioLegend 353416
ICOS C398.4A APC/Fire 750 BioLegend 313536
CD49b P1E6-C5 APC BioLegend 359310
CD25 BC96 APC/Fire 750 BioLegend 302642
CD4 SK3 FITC BioLegend 344604
Lag-3 11C3C65 PerCP BioLegend 369312
CD127 A019D5 PE BioLegend 351304
IL-10 JES3-9D7 PE-Cy7 BioLegend 501420
FOXP3 206D BV421 BioLegend 320124
PD-1 MIH4 PE-Cy7 eBioscience 25-9969-42
Abbreviations: APC, allophycocyanin; No., number.









25e50 6 75 8 57
>50 2 25 5 36
Mean 46 (29e63) 42 (30e54)
Gender
Male 2 25 9 64
Female 6 75 5 36
Skin type1
Type 1 0 1 7
Type 2 5 62.5 7 50
Type 3 3 37.5 5 36
Type 4 0 0
Type 5 0 1 7
Type 6 0 0
Comorbidities 1 12.5 5 36
Vitiligo age of onset (y), mean 32 13.9 34 19.1
Disease duration (y), median 7 (4e11.3) 8 (4.5e20)
% Affected body surface area median 1 (1e4) 1.5 (0.5e4.6)
Abbreviations: IQR, interquartile range; NSV, nonsegmental vitiligo.
1Skin type according to the Fitzpatrick skin scale.
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